Diabetes Leadership Edge: Advancing PA Leadership in the Management of Type 2 Diabetes | Module 4 - Pharmacotherapy Part 1: Treatment Algorithm and Non-Insulin Therapies
This interactive module is four of five designed to prepare PAs to effectively care for patients affected by diabetes.

Module 4 - Pharmacotherapy Part 1: Treatment Algorithm and Non-Insulin Therapies

Ji Chun, PA-C, MPAS, BC-ADM; Mary P. Ettari, PA, MPH; Ashlyn Smith, PA-C, MMS; Corri Wolf, PA-C, MS, RD

This module focuses on current standards of practice in type 2 diabetes management.

Educational Objectives

At the conclusion of this activity, you should be able to:
  • Outline an overall approach to treating type 2 diabetes, consistent with the ADA Standards of Medical Care in Diabetes and the AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm.
  • Set appropriate patient centered A1C targets based on clinical characteristics.
  • Identify how clinical inertia contributes to patients spending extended periods of time out of glycemic control and outline strategies to overcome it.
  • Review oral agents used in the management of type 2 diabetes including mechanism of action and general principles of use.
  • Provide a rationale for choosing a second agent based on patient characteristics and specific clinical conditions, and on what can be achieved by the addition of the agent in terms of glucose control and other potential benefits.
  • Review potential adverse events and approaches to managing them when they occur.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credit by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval valid until June 30, 2020.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Program Developers

Optum Medical Partners: Endocrinology
Orange County, CA
Faculty, A.T. Still University
Secretary, American Society of Endocrine PAs
No commercial relationships to disclose

Mary P. Ettari, PA, MPH
Volunteers in Medicine Clinic
Stuart, FL
Disclosures: Consultant for Johnson & Johnson

Ashlyn Smith, PA-C, MMS
Endocrinology Associates, PA
Scottsdale, AZ
No commercial relationships to disclose

Corri Wolf, PA-C, MS, RD
Associate Professor
Department of PA Studies
New York Institute of Technology
Old Westbury, NY
No commercial relationships to disclose

Activity Planners

Marie-Michele Leger, MPH, PA-C
Alexandria, VA
Employment - AAPA

Eric Peterson
Alexandria, VA
Employment - AAPA

Off-Label/Unapproved Product(s) Discussion

There are no references to off-label/unapproved uses of products in this program. 


The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Acknowledgement of Commercial Support

Supported by an educational grant from Novo Nordisk

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.

Type:     Internet Activity (Enduring Material)
1166 Registered Users